Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market was valued at USD 14 billion in 2022 and poised to reach USD 18.3 billion by 2029 growing at a CAGR of 5.0% during the forecast period 2022 to 2028. Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucose-dependent manner and by reduction of glucagon secretion.

https://www.precisionbusinessinsights.com/market-reports/global-dipeptidyl-peptidase-iv-dpp-iv-inhibitors-market